Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Effect of tocotrienol from Bixa orellana (annatto) on bone microstructure, calcium content, and biomechanical strength in a model of male osteoporosis induced by buserelin.

Mohamad NV, Ima-Nirwana S, Chin KY.

Drug Des Devel Ther. 2018 Mar 16;12:555-564. doi: 10.2147/DDDT.S158410. eCollection 2018.

2.

Discrimination of local recurrence after radical prostatectomy: value of diffusion-weighted magnetic resonance imaging.

Kwon T, Kim JK, Lee C, Jung J, Ahn H, Kim CS, Hong JH.

Prostate Int. 2018 Mar;6(1):12-17. doi: 10.1016/j.prnil.2017.05.002. Epub 2017 May 25.

3.
4.

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.

Yang YJ, Lin GW, Li GX, Dai B, Ye DW, Wu JL, Xie HY, Zhu Y.

Asian J Androl. 2018 Mar-Apr;20(2):184-188. doi: 10.4103/aja.aja_39_17.

5.

Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.

Yu P, Duan X, Cheng Y, Liu C, Chen Y, Liu W, Yin B, Wang X, Tao Z.

Int J Mol Med. 2017 Nov;40(5):1426-1434. doi: 10.3892/ijmm.2017.3125. Epub 2017 Sep 7.

6.

Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders.

Leow JJ, Cole AP, Sun M, Trinh QD.

J Clin Oncol. 2016 Aug 10;34(23):2801-3. doi: 10.1200/JCO.2016.66.6594. Epub 2016 Jun 13. No abstract available.

7.

The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds.

Rutkowski MR, Svoronos N, Perales-Puchalt A, Conejo-Garcia JR.

Adv Cancer Res. 2015;128:235-62. doi: 10.1016/bs.acr.2015.04.011. Epub 2015 May 21. Review.

8.

Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy.

Barchetti F, Panebianco V.

Biomed Res Int. 2014;2014:316272. doi: 10.1155/2014/316272. Epub 2014 May 25. Review.

9.

Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.

Panebianco V, Barchetti F, Musio D, De Felice F, Proietti C, Indino EL, Megna V, Schillaci O, Catalano C, Tombolini V.

Biomed Res Int. 2014;2014:827265. doi: 10.1155/2014/827265. Epub 2014 Mar 13. Review.

10.

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT.

Mol Cancer Ther. 2014 May;13(5):1246-58. doi: 10.1158/1535-7163.MCT-13-0605. Epub 2014 Feb 27.

11.

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.

Akaza H, Hinotsu S, Usami M, Ogawa O, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M.

Prostate Int. 2013;1(2):81-8. doi: 10.12954/PI.12016. Epub 2013 Jun 30.

12.

Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.

Huang TY, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS.

World J Surg Oncol. 2013 Oct 2;11:254. doi: 10.1186/1477-7819-11-254.

13.

STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, Visakorpi T, Bubendorf L, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Nevalainen MT.

Am J Pathol. 2013 Jun;182(6):2264-75. doi: 10.1016/j.ajpath.2013.02.044. Epub 2013 May 7.

14.

An economic analysis of conservative management versus active treatment for men with localized prostate cancer.

Perlroth DJ, Bhattacharya J, Goldman DP, Garber AM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):250-7. doi: 10.1093/jncimonographs/lgs037.

15.

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.

Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS.

Med Sci Monit. 2012 Apr;18(4):CR260-4.

16.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Connolly RM, Carducci MA, Antonarakis ES.

Asian J Androl. 2012 Mar;14(2):177-86. doi: 10.1038/aja.2011.103. Epub 2012 Jan 9. Review.

17.

Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.

Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, Jannini EA, Festuccia C.

Endocrinology. 2011 Dec;152(12):4550-61. doi: 10.1210/en.2011-1056. Epub 2011 Oct 11.

18.

A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.

Lin YH, Chen CL, Hou CP, Chang PL, Tsui KH.

Acta Pharmacol Sin. 2011 Apr;32(4):537-42. doi: 10.1038/aps.2010.236. Epub 2011 Mar 14.

19.

Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment.

Lin HC, Wu HC, Chang CH, Li TC, Liang WM, Wang JY.

BMC Med Inform Decis Mak. 2011 Mar 8;11:16. doi: 10.1186/1472-6947-11-16.

20.

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB.

J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419. Epub 2010 Nov 10.

Supplemental Content

Support Center